Skip to content

The ParkCycle Study: Aerobic Exercise in PD

The ParkCycle Study: Effects of Aerobic Exercise on Cognitive and Adaptive Plasticity in Parkinson's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01562496
Enrollment
35
Registered
2012-03-23
Start date
2012-01-31
Completion date
2014-10-31
Last updated
2014-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's disease, Neuroprotective, Intensive exercise

Brief summary

The primary goal of this study is to determine the neuroprotective qualities of long-term, in home, exercise therapy program in human PD patients. It is hypothesized that an exercise intervention might delay the onset of levo-dopa therapy (i.e. evidence for neuroprotection). The first part involves a pilot-study in which the feasibility of the intervention and outcome measures will be tested.

Detailed description

Neuroprotective therapy (i.e. therapy that slows the disease process) is an unmet medical need in Parkinson's disease (PD). Animal studies have shown that 'intensive' exercise improves motor function and may have neuroprotective properties. The promising animal results have not been translated to patients with PD so far. This is a two-cluster randomised control trial in which twenty patients (10 at each site) will undergo a 6-month exercise intervention on a stationary virtual reality bike and twenty patients (10 at each site)will serve as controls.

Interventions

BEHAVIORALExercise

six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).

Sponsors

The Cleveland Clinic
CollaboratorOTHER
Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of idiopathic Parkinson's disease according to the UK Queen Square Brain Bank Criteria * Hoehn & Yahr disease stages I-II * Age between 30 and 75 years * Having insufficient physical activity according to the ACSM guideline for adults, 50-64 years old with a chronic condition * Untreated with anti-parkinsonian medication or receiving medication, for less than two years, medication-responsive without fluctuations.

Exclusion criteria

* Unclear diagnosis with Red Flags * Advanced problems in cognitive functioning: Mini Mental State Examination (MMSE)19 score \< 24 * Serious co-morbidity: neurological or orthopedic disorder that severely affects movement; known by specialist or medical practitioner * Pulmonary diseases; known by specialist or medical practitioner * Stroke * High risk of cardiovascular complications: * Hypertension (systole \>150 and diastole \> 100) * Diabetes Mellitus; known by specialist or medical practitioner * Cardiac valve defect (especially aortic valve stenosis); known by specialist or medical practitioner * Cardiac rhythm disorder; known by specialist or medical practitioner * Heart failure; known by specialist or medical practitioner * Use of ß-blockers * Not able to complete American (for Cleveland site) or Dutch questionnaires (for the Nijmegen site) * Daily institutionalized care * Contra-indications for fMRI: * Pregnancy * Metallic implants or electronic devices * Previous seizure * Claustrophobia * Not able to keep the head still for longer period, i.e. due to severe head tremor

Design outcomes

Primary

MeasureTime frameDescription
Trails A and B taskevery month for 6-7 monthsthis test requires subjects to connect numbers on a screen from 1 to 25 (part A) and to connect numbers to letters. This neuropsychological test has already been proven to be sensitive to frontal lobe damage (e.g. Boll 1981) and has been recognised as an outcome for executive function in PD21. This test is performed using an online system called i-COMET that allows subject to complete the task weekly at home. Subjects have to login at the i-COMET website (https://i-comet.com) with a username and password that is provided to them by the research team.

Secondary

MeasureTime frameDescription
Cognitive testsbaseline and after 6 months FUMMSE and SCOPA-org
Kinetics testsbaseline and after 6 months FUTimed Up and Go Test (iTUG) and a postural sway test, , as an objective measure for balance and mobility Finger tap test as a measure for bradykinesia and a pegboard test as a measure for complex motor function
questionairesbaseline and after 6 months FUThe PDQ-39 is a PD specific questionnaire including 39 items concerning quality of life. Other non-motor features such as mood and sleep are respectively measured using the HADS and SCOPA-Sleep.
UPDRSbaseline and after 6 months follow-up (FU)
feasibility parametersafter 6 months (termination of intervention)Compliance based on the number of completed exercise sessions and the amount of time that patients exercised at their target heart rate.
neuroplasticitybaseline and after 6 months FU1. Volumetric brain changes: cerebral grey and white matter will be analyzed using Vox-Based Morphometry, a validated and fully automated technique for computational analysis of differences in global and local grey and/or white matter volume. 2. Resting state brain perfusion: functional coupling between strial subregions and the cerebral cortex will be analyzed using multiple regression analyses on resting state functional MRI data.
maximal exercise testbaseline and after 6 months FUto determine training load and subject fitness

Countries

Netherlands, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026